GoodRx Holdings (GDRX) Change in Accured Expenses (2019 - 2026)

GoodRx Holdings' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 1025.16% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $2.8 million (up 226.61% YoY), while the FY2025 annual figure was $1.2 million, up 183.33% from the prior year.
• Change in Accured Expenses came in at $1.7 million for Q1 2026 at GoodRx Holdings, up from -$41.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $45.4 million in Q3 2025 to a low of -$41.0 million in Q4 2025.
• A 5-year average of $1.5 million and a median of $405000.0 in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 24892.11% in 2022 and fell as far as 4108.62% in 2022.
• GoodRx Holdings' Change in Accured Expenses stood at -$7.0 million in 2022, then jumped by 397.69% to $20.8 million in 2023, then sank by 202.14% to -$21.2 million in 2024, then sank by 93.5% to -$41.0 million in 2025, then surged by 104.25% to $1.7 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $1.7 million, -$41.0 million, and $45.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison